DelveInsight’s market analysis demonstrates robust growth in AI-driven precision medicine, highlighting how advanced algorithms process genomic and clinical data to optimize personalized diagnostics and therapies, driven by partnerships and FDA clearances in North America leading the global market through 2032.

Key points

• Hardware and software accounted for the largest revenue share in the AI in precision medicine market in 2024.
• North America is projected to dominate the global AI precision medicine market through 2032, driven by R&D and regulatory clearances.
• Major partnerships and FDA 510(k) approvals, including Illumina-Tempus and Ibex Prostate Detect, are accelerating clinical adoption.

Why it matters: The projected 33% CAGR underscores AI's transformative impact on personalized healthcare, promising faster diagnostics and tailored treatments beyond conventional methods.